Search the GHTC website

Global health R&D delivers for Connecticut

US government investment in global health R&D has delivered

$273.8 million
to Connecticut research institutions
2,700+ new jobs
for Connecticut
Connecticut's top USG-funded global health R&D institutions

Connecticut's top USG-funded global health R&D institutions

Yale University
$211.9 million
University of Connecticut School of Medicine
$22.4 million
University of Connecticut (Storrs)
$14.6 million
L2 Diagnostics LLC
$9.3 million
Artificial Cell Technologies Inc.
$4.2 million
New England Institute for Clinical Research
$2.7 million
CaroGen Corporation
$2 million
Connecticut Children's Medical Center
$2 million
Connecticut Agricultural Experiment Station
$1.1 million
LifePharms Inc.*
$750 thousand
MediSynergics LLC
$724 thousand
Tangen Biosciences Inc.
$716 thousand
New England Discovery Partners LLC
$701 thousand
Wesleyan University
$587 thousand
Connecticut Analytical Corporation (CAC)
$167 thousand
UConn Health (formerly University of Connecticut Health Center)
$61 thousand

Connecticut's top areas of global health R&D by USG funding

Diarrheal diseases
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Salmonella infections
Arenaviral hemorrhagic fevers (including Lassa fever)
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Hepatitis B
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Global health R&D at work in Connecticut

Scientists at the University of Connecticut Center of Excellence for Vaccine Research in Storrs have developed a potential vaccine against Zika using a new platform devised by the center to speed an early stage of vaccine development, which has proved successful in preclinical testing. Using this technique, researchers can create a prospective vaccine in a week, rather than months, allowing them to generate multiple variations of a vaccine quickly for further testing. Beyond contributing to the fight against Zika, this technique also could potentially speed vaccine development against many other long-standing and emerging global health threats.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Dan Chang